SlideShare una empresa de Scribd logo
1 de 8
Descargar para leer sin conexión
Weisberg Consulting, LLC



  15	
  Benedict	
  Crescent 	
      	
         	
  Tel:	
  (732)	
  773-­‐4332	
  
  Basking	
  Ridge,	
  NJ	
  07920   	
  	
     	
  Email:	
  iraweis@optonline.net	
  	
  
About Us
     Weisberg	
  ConsulGng	
  derives	
  its	
  experGse	
  with	
  an	
  extensive	
  experience	
  in	
  
      business	
  and	
  corporate	
  development	
  as	
  well	
  as	
  building	
  brands	
  and	
  companies	
  
      both	
  in	
  the	
  United	
  States	
  as	
  well	
  as	
  internaGonal	
  markets.	
  	
  
     Structured	
  along	
  the	
  lines	
  of	
  a	
  pharmaceuGcal	
  company,	
  we	
  have	
  four	
  areas	
  of	
  
      specialty:	
  	
  
         Corporate	
  and	
  Business	
  Development	
  

         Market	
  intelligence	
  

         Brand	
  management	
  

         Brand	
  and	
  corporate	
  strategy.	
  	
  	
  

     The	
  integraGon	
  of	
  these	
  specialGes	
  allows	
  for	
  the	
  development	
  of	
  stakeholder-­‐
      driven	
  and	
  fact-­‐based	
  strategies.	
  This	
  approach	
  has	
  repeatedly	
  generated	
  
      substanGal	
  and	
  sustainable	
  growth,	
  even	
  in	
  mature	
  markets	
  –	
  providing	
  clarity,	
  
      control	
  and	
  confidence	
  in	
  strategy	
  to	
  improve	
  both	
  brand	
  and	
  business	
  
      performance.	
  	
  
Key Transactions

 M&A/Out-­‐licensing	
  Deals	
  
   IniGated	
  and	
  closed	
  on	
  a	
  $105	
  million	
  transacGon	
  with	
  Cowen	
  Healthcare	
  Royalty	
  in	
  which	
  we	
  
    moneGzed	
  the	
  royalty	
  stream	
  of	
  a	
  key	
  product	
  
   NegoGated	
  several	
  off-­‐shore	
  licensing	
  deals	
  on	
  several	
  key	
  products	
  
   Raised	
  iniGal	
  funding	
  for	
  the	
  development	
  of	
  a	
  new	
  company	
  involved	
  in	
  an	
  innovaGve	
  
    cardiovascular	
  therapeuGc.	
  
   Led	
  acquisiGon	
  of	
  a	
  business	
  from	
  Baxter	
  Healthcare	
  enabling	
  company	
  to	
  be	
  first	
  entrant	
  into	
  
    $400	
  million	
  US	
  market.	
  
   Generated	
  proceeds	
  of	
  $30	
  million	
  in	
  IPO	
  providing	
  capital	
  for	
  growth	
  and	
  product	
  development.	
  
   Concluded	
  an	
  iniGal	
  round	
  of	
  funding	
  with	
  a	
  mid-­‐west	
  venture	
  capital	
  group	
  for	
  $3.5	
  million;	
  
    leading	
  the	
  efforts	
  to	
  raise	
  an	
  addiGonal	
  $9	
  million	
  in	
  a	
  Series	
  A	
  financing	
  for	
  a	
  cardiovascular	
  
    product	
  
   Out-­‐licensed	
  a	
  GI	
  opportunity	
  to	
  a	
  specialty	
  pharmaceuGcal	
  company	
  –	
  Deal	
  Value:	
  $150	
  million	
  
   Out-­‐licensed	
  an	
  oncology/immune-­‐enhancement	
  biologic	
  to	
  a	
  mid-­‐sized	
  pharmaceuGcal	
  company	
  
    –	
  Deal	
  Value:	
  $200	
  million	
  
   Divested	
  the	
  viral	
  tesGng	
  business	
  of	
  AvenGs	
  Behring	
  to	
  NaGonal	
  GeneGcs	
  InsGtute,	
  subsidiary	
  of	
  
    LabCorp	
  
Key Transactions
 Other	
  Deals	
  
   IniGated	
  and	
  closed	
  on	
  a	
  partnering	
  arrangement	
  to	
  enhance	
  product	
  
    development	
  and	
  add	
  new	
  products	
  into	
  the	
  development	
  pordolio	
  
   Led	
  negoGaGons	
  on	
  the	
  acquisiGon	
  of	
  a	
  cardiovascular	
  opportunity	
  –	
  Deal	
  
    Value:	
  $500	
  million	
  
   Led	
  the	
  development	
  of	
  a	
  global	
  recombinant	
  albumin	
  business	
  valued	
  in	
  
    excess	
  of	
  $750	
  million;	
  negoGated	
  out-­‐licensing	
  agreements	
  with	
  a	
  
    number	
  of	
  major	
  pharmaceuGcal	
  companies	
  
   NegoGated	
  a	
  Licensing	
  Agreement	
  with	
  the	
  leading	
  global	
  medical	
  device	
  
    company	
  –	
  Deal	
  Value:	
  $650	
  million	
  
   NegoGated	
  a	
  Supply	
  and	
  DistribuGon	
  Agreement	
  that	
  resulted	
  a	
  net	
  in	
  
    excess	
  of	
  $100	
  million	
  over	
  several	
  years	
  	
  
Key Transactions
 Other	
  Deals	
  (cont’d)	
  
   NegoGated	
  a	
  licensing	
  and	
  development	
  agreement	
  with	
  a	
  leading	
  pulmonary	
  
    delivery	
  device	
  firm	
  with	
  a	
  deal	
  value	
  of	
  $350	
  million	
  
   NegoGated	
  a	
  licensing	
  and	
  development	
  agreement	
  for	
  a	
  specialty	
  medical	
  
    product	
  valued	
  at	
  $500	
  million	
  
   NegoGated	
  agreement	
  for	
  the	
  distribuGon	
  of	
  acquired	
  products	
  in	
  US.	
  
   Developed	
  exclusive	
  global	
  contract	
  manufacturing	
  agreement	
  with	
  European	
  
    company,	
  	
  
    avoiding	
  expense	
  of	
  $75	
  million	
  for	
  construcGon	
  of	
  manufacturing	
  facility.	
  
   Managed	
  transfer	
  of	
  proprietary	
  technology	
  to	
  European	
  manufacturer,	
  
    completed	
  in	
  less	
  than	
  	
  
    twelve	
  months	
  at	
  75%	
  of	
  originally	
  budgeted	
  cost.	
  
   Led	
  the	
  negoGaGon	
  of	
  a	
  License	
  Agreement	
  for	
  a	
  monoclonal-­‐based	
  pladorm	
  
    opportunity	
  Deal	
  Value:	
  $350	
  million	
  
The Licensing Process
 Our	
  goal	
  is	
  to	
  idenGfy	
  licensors	
  for	
  hard	
  to	
  license	
  
 products.	
  This	
  is	
  done	
  by	
  conducGng	
  the	
  following	
  
 analyses:	
  
   What	
  strategic	
  gaps	
  in	
  pipeline	
  or	
  pordolio	
  need	
  to	
  
    be	
  filled	
  to	
  by	
  the	
  candidate	
  licensor?	
  
   What	
  are	
  the	
  underlying	
  dynamics	
  of	
  the	
  product	
  
    to	
  be	
  licensed?	
  
   How	
  will	
  potenGal	
  licensors	
  relate	
  to	
  the	
  product?	
  
   Which	
  markeGng	
  levers	
  will	
  drive	
  growth	
  the	
  
    product?	
  
The Licensing Process
 Our	
  approach	
  will	
  provide	
  a	
  structural	
  
 understanding	
  of	
  the	
  product	
  to	
  be	
  licensed.	
  We	
  
 structure,	
  source	
  and	
  analyze	
  informaBon	
  in	
  a	
  
 manner	
  that	
  provides	
  a	
  360o	
  perspecBve	
  of	
  the	
  
 product.	
  Such	
  a	
  perspecBve	
  drives	
  decision	
  making	
  
 differently.	
  We	
  will	
  provide	
  clarity	
  and	
  transparency	
  
 on	
  brand	
  performance	
  issues	
  as	
  well	
  as	
  provide	
  
 insight	
  into	
  untapped	
  sources	
  of	
  business.	
  
                                                                                         The	
  success	
  of	
  any	
  brand	
  is	
  based	
  on	
  a	
  number	
  
                                                                                         of	
  interconnected	
  elements.	
  We	
  will	
  idenBfy	
  
                                                                                         which	
  of	
  these	
  levers	
  drives	
  performance	
  of	
  
                                                                                         your	
  brand	
  and	
  provides	
  effecBve	
  control	
  over	
  
                                                                                         its	
  execuBon.	
  	
  

 Our	
  iteraBve	
  and	
  highly	
  dynamic	
  modeling	
  approach	
  enables	
  you	
  
 to	
  explore,	
  test	
  and	
  analyze	
  a	
  range	
  of	
  plausible	
  strategic	
  scenarios	
  
 in	
  a	
  risk-­‐free	
  environment.	
  	
  Our	
  custom	
  built	
  tools	
  provide	
  a	
  high	
  
 degree	
  of	
  confidence	
  in	
  the	
  chosen	
  strategy	
  for	
  building	
  superior	
  
 brand	
  performance.	
  
Weisberg Consulting, LLC



   15	
  Benedict	
  Crescent       	
         	
              	
  Tel:	
  (732)	
  773-­‐4332	
  
   Basking	
  Ridge,	
  NJ	
  07920 	
  	
     	
  Email:	
  iraweis@optonline.net	
  	
  

Más contenido relacionado

Destacado

CMTupdate summer 2014
CMTupdate summer 2014CMTupdate summer 2014
CMTupdate summer 2014Sean Ekins
 
презентация ольги штемберг 11 марта
презентация ольги штемберг 11 мартапрезентация ольги штемберг 11 марта
презентация ольги штемберг 11 мартаeconadin
 
22. болезни кишечника
22. болезни кишечника22. болезни кишечника
22. болезни кишечникаcdo_presentation
 
Three Ways to Skin a Copycat: Design Patents, Trade Dress and Copyright
Three Ways to Skin a Copycat: Design Patents, Trade Dress and CopyrightThree Ways to Skin a Copycat: Design Patents, Trade Dress and Copyright
Three Ways to Skin a Copycat: Design Patents, Trade Dress and Copyrightscottsicle
 

Destacado (8)

CMTupdate summer 2014
CMTupdate summer 2014CMTupdate summer 2014
CMTupdate summer 2014
 
Savtira PR 4-3-11 NGConnect
Savtira PR 4-3-11 NGConnectSavtira PR 4-3-11 NGConnect
Savtira PR 4-3-11 NGConnect
 
Banco raz mat ii parcial
Banco raz mat ii parcialBanco raz mat ii parcial
Banco raz mat ii parcial
 
презентация ольги штемберг 11 марта
презентация ольги штемберг 11 мартапрезентация ольги штемберг 11 марта
презентация ольги штемберг 11 марта
 
22. болезни кишечника
22. болезни кишечника22. болезни кишечника
22. болезни кишечника
 
Three Ways to Skin a Copycat: Design Patents, Trade Dress and Copyright
Three Ways to Skin a Copycat: Design Patents, Trade Dress and CopyrightThree Ways to Skin a Copycat: Design Patents, Trade Dress and Copyright
Three Ways to Skin a Copycat: Design Patents, Trade Dress and Copyright
 
Ahmedkorra cv
Ahmedkorra cvAhmedkorra cv
Ahmedkorra cv
 
Investment Acceleration Special Measures
Investment Acceleration Special MeasuresInvestment Acceleration Special Measures
Investment Acceleration Special Measures
 

Similar a Weisberg Consulting Introduction

Aditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) PresentationAditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) PresentationRedChip Companies, Inc.
 
GTM Automation - the Infrastructure of Global Supply Chains
GTM Automation - the Infrastructure of Global Supply ChainsGTM Automation - the Infrastructure of Global Supply Chains
GTM Automation - the Infrastructure of Global Supply ChainsGrant Sernick
 
PSID - Global Online Growth Conference Oct 2016
PSID - Global Online Growth Conference Oct 2016PSID - Global Online Growth Conference Oct 2016
PSID - Global Online Growth Conference Oct 2016RedChip Companies, Inc.
 
The Upper Hand of Innovation: Using Competitive Intelligence to Drive Product...
The Upper Hand of Innovation: Using Competitive Intelligence to Drive Product...The Upper Hand of Innovation: Using Competitive Intelligence to Drive Product...
The Upper Hand of Innovation: Using Competitive Intelligence to Drive Product...Arik Johnson
 
Stabicon Outsourcing Presentation
Stabicon Outsourcing PresentationStabicon Outsourcing Presentation
Stabicon Outsourcing PresentationStabicon123
 
Syngene Ipo Note - Subscribe for long term gains
Syngene Ipo Note - Subscribe for long term gainsSyngene Ipo Note - Subscribe for long term gains
Syngene Ipo Note - Subscribe for long term gainsIndiaNotes.com
 
4.4.15 Business Model
4.4.15 Business Model4.4.15 Business Model
4.4.15 Business ModelSteven Sable
 
ALR resume Sept 2015
ALR resume Sept 2015ALR resume Sept 2015
ALR resume Sept 2015specphrm
 
Svmk investor presentation november 2019
Svmk investor presentation november 2019Svmk investor presentation november 2019
Svmk investor presentation november 2019EmilyGreenstein4
 
Global Business and Financial Consultant For SMEs, Startups
Global Business and Financial Consultant For SMEs, StartupsGlobal Business and Financial Consultant For SMEs, Startups
Global Business and Financial Consultant For SMEs, StartupsDNA Growth
 
Salesforce - NOAH17 Berlin
Salesforce - NOAH17 BerlinSalesforce - NOAH17 Berlin
Salesforce - NOAH17 BerlinNOAH Advisors
 
1001205101
10012051011001205101
1001205101veriskir
 
Faster business decisions and collaboration with Elastic Workplace Search
Faster business decisions and collaboration with Elastic Workplace SearchFaster business decisions and collaboration with Elastic Workplace Search
Faster business decisions and collaboration with Elastic Workplace SearchElasticsearch
 

Similar a Weisberg Consulting Introduction (20)

Cdxc 102013
Cdxc 102013Cdxc 102013
Cdxc 102013
 
Aditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) PresentationAditxt, Inc. (NASDAQ: ADTX) Presentation
Aditxt, Inc. (NASDAQ: ADTX) Presentation
 
Cdxc 6262013
Cdxc 6262013Cdxc 6262013
Cdxc 6262013
 
PositiveID Corporation (OTCQB: PSID)
PositiveID Corporation (OTCQB: PSID)PositiveID Corporation (OTCQB: PSID)
PositiveID Corporation (OTCQB: PSID)
 
PositiveID Investor Presentation
PositiveID Investor PresentationPositiveID Investor Presentation
PositiveID Investor Presentation
 
GTM Automation - the Infrastructure of Global Supply Chains
GTM Automation - the Infrastructure of Global Supply ChainsGTM Automation - the Infrastructure of Global Supply Chains
GTM Automation - the Infrastructure of Global Supply Chains
 
Positive ID Presentation
Positive ID PresentationPositive ID Presentation
Positive ID Presentation
 
PSID - Global Online Growth Conference Oct 2016
PSID - Global Online Growth Conference Oct 2016PSID - Global Online Growth Conference Oct 2016
PSID - Global Online Growth Conference Oct 2016
 
The Upper Hand of Innovation: Using Competitive Intelligence to Drive Product...
The Upper Hand of Innovation: Using Competitive Intelligence to Drive Product...The Upper Hand of Innovation: Using Competitive Intelligence to Drive Product...
The Upper Hand of Innovation: Using Competitive Intelligence to Drive Product...
 
Stabicon Outsourcing Presentation
Stabicon Outsourcing PresentationStabicon Outsourcing Presentation
Stabicon Outsourcing Presentation
 
Syngene Ipo Note - Subscribe for long term gains
Syngene Ipo Note - Subscribe for long term gainsSyngene Ipo Note - Subscribe for long term gains
Syngene Ipo Note - Subscribe for long term gains
 
BFRG Presentation
BFRG PresentationBFRG Presentation
BFRG Presentation
 
4.4.15 Business Model
4.4.15 Business Model4.4.15 Business Model
4.4.15 Business Model
 
ALR resume Sept 2015
ALR resume Sept 2015ALR resume Sept 2015
ALR resume Sept 2015
 
Svmk investor presentation november 2019
Svmk investor presentation november 2019Svmk investor presentation november 2019
Svmk investor presentation november 2019
 
Global Business and Financial Consultant For SMEs, Startups
Global Business and Financial Consultant For SMEs, StartupsGlobal Business and Financial Consultant For SMEs, Startups
Global Business and Financial Consultant For SMEs, Startups
 
Salesforce - NOAH17 Berlin
Salesforce - NOAH17 BerlinSalesforce - NOAH17 Berlin
Salesforce - NOAH17 Berlin
 
1001205101
10012051011001205101
1001205101
 
Faster business decisions and collaboration with Elastic Workplace Search
Faster business decisions and collaboration with Elastic Workplace SearchFaster business decisions and collaboration with Elastic Workplace Search
Faster business decisions and collaboration with Elastic Workplace Search
 
Resume Paul Rohricht MS, MBA
Resume Paul Rohricht MS, MBAResume Paul Rohricht MS, MBA
Resume Paul Rohricht MS, MBA
 

Weisberg Consulting Introduction

  • 1. Weisberg Consulting, LLC 15  Benedict  Crescent      Tel:  (732)  773-­‐4332   Basking  Ridge,  NJ  07920      Email:  iraweis@optonline.net    
  • 2. About Us   Weisberg  ConsulGng  derives  its  experGse  with  an  extensive  experience  in   business  and  corporate  development  as  well  as  building  brands  and  companies   both  in  the  United  States  as  well  as  internaGonal  markets.       Structured  along  the  lines  of  a  pharmaceuGcal  company,  we  have  four  areas  of   specialty:       Corporate  and  Business  Development     Market  intelligence     Brand  management     Brand  and  corporate  strategy.         The  integraGon  of  these  specialGes  allows  for  the  development  of  stakeholder-­‐ driven  and  fact-­‐based  strategies.  This  approach  has  repeatedly  generated   substanGal  and  sustainable  growth,  even  in  mature  markets  –  providing  clarity,   control  and  confidence  in  strategy  to  improve  both  brand  and  business   performance.    
  • 3. Key Transactions M&A/Out-­‐licensing  Deals     IniGated  and  closed  on  a  $105  million  transacGon  with  Cowen  Healthcare  Royalty  in  which  we   moneGzed  the  royalty  stream  of  a  key  product     NegoGated  several  off-­‐shore  licensing  deals  on  several  key  products     Raised  iniGal  funding  for  the  development  of  a  new  company  involved  in  an  innovaGve   cardiovascular  therapeuGc.     Led  acquisiGon  of  a  business  from  Baxter  Healthcare  enabling  company  to  be  first  entrant  into   $400  million  US  market.     Generated  proceeds  of  $30  million  in  IPO  providing  capital  for  growth  and  product  development.     Concluded  an  iniGal  round  of  funding  with  a  mid-­‐west  venture  capital  group  for  $3.5  million;   leading  the  efforts  to  raise  an  addiGonal  $9  million  in  a  Series  A  financing  for  a  cardiovascular   product     Out-­‐licensed  a  GI  opportunity  to  a  specialty  pharmaceuGcal  company  –  Deal  Value:  $150  million     Out-­‐licensed  an  oncology/immune-­‐enhancement  biologic  to  a  mid-­‐sized  pharmaceuGcal  company   –  Deal  Value:  $200  million     Divested  the  viral  tesGng  business  of  AvenGs  Behring  to  NaGonal  GeneGcs  InsGtute,  subsidiary  of   LabCorp  
  • 4. Key Transactions Other  Deals     IniGated  and  closed  on  a  partnering  arrangement  to  enhance  product   development  and  add  new  products  into  the  development  pordolio     Led  negoGaGons  on  the  acquisiGon  of  a  cardiovascular  opportunity  –  Deal   Value:  $500  million     Led  the  development  of  a  global  recombinant  albumin  business  valued  in   excess  of  $750  million;  negoGated  out-­‐licensing  agreements  with  a   number  of  major  pharmaceuGcal  companies     NegoGated  a  Licensing  Agreement  with  the  leading  global  medical  device   company  –  Deal  Value:  $650  million     NegoGated  a  Supply  and  DistribuGon  Agreement  that  resulted  a  net  in   excess  of  $100  million  over  several  years    
  • 5. Key Transactions Other  Deals  (cont’d)     NegoGated  a  licensing  and  development  agreement  with  a  leading  pulmonary   delivery  device  firm  with  a  deal  value  of  $350  million     NegoGated  a  licensing  and  development  agreement  for  a  specialty  medical   product  valued  at  $500  million     NegoGated  agreement  for  the  distribuGon  of  acquired  products  in  US.     Developed  exclusive  global  contract  manufacturing  agreement  with  European   company,     avoiding  expense  of  $75  million  for  construcGon  of  manufacturing  facility.     Managed  transfer  of  proprietary  technology  to  European  manufacturer,   completed  in  less  than     twelve  months  at  75%  of  originally  budgeted  cost.     Led  the  negoGaGon  of  a  License  Agreement  for  a  monoclonal-­‐based  pladorm   opportunity  Deal  Value:  $350  million  
  • 6. The Licensing Process Our  goal  is  to  idenGfy  licensors  for  hard  to  license   products.  This  is  done  by  conducGng  the  following   analyses:     What  strategic  gaps  in  pipeline  or  pordolio  need  to   be  filled  to  by  the  candidate  licensor?     What  are  the  underlying  dynamics  of  the  product   to  be  licensed?     How  will  potenGal  licensors  relate  to  the  product?     Which  markeGng  levers  will  drive  growth  the   product?  
  • 7. The Licensing Process Our  approach  will  provide  a  structural   understanding  of  the  product  to  be  licensed.  We   structure,  source  and  analyze  informaBon  in  a   manner  that  provides  a  360o  perspecBve  of  the   product.  Such  a  perspecBve  drives  decision  making   differently.  We  will  provide  clarity  and  transparency   on  brand  performance  issues  as  well  as  provide   insight  into  untapped  sources  of  business.   The  success  of  any  brand  is  based  on  a  number   of  interconnected  elements.  We  will  idenBfy   which  of  these  levers  drives  performance  of   your  brand  and  provides  effecBve  control  over   its  execuBon.     Our  iteraBve  and  highly  dynamic  modeling  approach  enables  you   to  explore,  test  and  analyze  a  range  of  plausible  strategic  scenarios   in  a  risk-­‐free  environment.    Our  custom  built  tools  provide  a  high   degree  of  confidence  in  the  chosen  strategy  for  building  superior   brand  performance.  
  • 8. Weisberg Consulting, LLC 15  Benedict  Crescent      Tel:  (732)  773-­‐4332   Basking  Ridge,  NJ  07920      Email:  iraweis@optonline.net